文献速递妇科

高stathmin表达是子宫内膜癌不良临床结局的标志:一项NRG肿瘤学组/妇科肿瘤学组研究

High stathmin expression is a marker for poor clinical outcome in endometrial cancer: An NRG oncology group/gynecologic oncology group study.
PubMed 文献 · Gynecol Oncol · 2017-05-19

该研究利用GOG-177试验中69例晚期或复发子宫内膜癌患者的标本,通过免疫组化分析stathmin表达,并在TCGA数据集中验证其mRNA表达与临床结局的相关性。结果显示,高stathmin表达与更短的无进展生存期(PFS)和总生存期(OS)显著相关,尤其在仅接受阿霉素/顺铂治疗的患者中;而在接受紫杉醇/阿霉素/顺铂治疗的患者中,stathmin表达与OS或PFS无统计学显著关联。作者认为紫杉醇可能有助于抵消stathmin过表达的影响。

要点

  • 高stathmin表达与子宫内膜癌患者更短的PFS和OS显著相关。
  • 在仅接受阿霉素/顺铂治疗的患者中,高stathmin与不良PFS和OS相关。
  • 在接受紫杉醇/阿霉素/顺铂治疗的患者中,stathmin表达与OS或PFS无统计学显著关联。

核心结论

  • 高stathmin表达是子宫内膜癌的不良预后标志。
  • 紫杉醇可能有助于抵消stathmin过表达的影响,用于治疗高风险子宫内膜癌病例。

研究设计与样本

  • 研究分析了GOG-177试验中69例患者的标本,通过免疫组化检测stathmin表达。
  • 同时在TCGA数据集中分析了stathmin mRNA表达与临床结局的相关性。

主要发现

  • 在GOG-177和TCGA的所有分析病例中,stathmin表达与更短的PFS和OS显著相关。
  • 在GOG-177的子组分析中,高stathmin与不良PFS和OS的相关性尤其见于仅接受阿霉素/顺铂治疗的患者。
  • 在接受紫杉醇/阿霉素/顺铂治疗的患者中,stathmin表达与OS或PFS无统计学显著关联。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Gynecologic Oncology Group (GOG) 177 demonstrated that addition of paclitaxel to a backbone of adriamycin/cisplatin improves overall survival (OS) and progression-free survival (PFS) for patients with advanced or recurrent endometrial cancer. Using patient specimens from GOG-177, our objective was to identify potential mechanisms underlying the improved clinical response to taxanes. Stathmin (STMN1) is a recognized poor prognostic marker in endometrial cancer that functions as a microtubule depolymerizing protein, allowing cells to transit rapidly through mitosis. Therefore, we hypothesized that one possible mechanism underlying the beneficial effects of paclitaxel could be to counter the impact of stathmin. METHODS: We analyzed the expression of stathmin by immunohistochemistry (IHC) in 69 specimens from patients enrolled on GOG-177. We also determined the correlation between stathmin mRNA expression and clinical outcomes in The Cancer Genome Atlas (TCGA) dataset for endometrial cancer. RESULTS: We first established that stathmin expression was significantly associated with shorter PFS and OS for all analyzed cases in both GOG-177 and TCGA. However, subgroup analysis from GOG-177 revealed that high stathmin correlated with poor PFS and OS particularly in patients who received adriamycin/cisplatin only. In contrast, there was no statistically significant association between stathmin expression and OS or PFS in patients treated with paclitaxel/adriamycin/cisplatin. CONCLUSIONS: Our findings demonstrate that high stathmin expression is a poor prognostic marker in endometrial cancer. Paclitaxel may help to negate the impact of stathmin overexpression when treating high risk endometrial cancer cases.

来源:Gynecol Oncol,查看原文。版权归原作者所有。

引用

  1. Reyes HD, Miecznikowski J, Gonzalez-Bosquet J, et al. High stathmin expression is a marker for poor clinical outcome in endometrial cancer: An NRG oncology group/gynecologic oncology group study. Gynecol Oncol. 2017. PMID: 28532857. doi:10.1016/j.ygyno.2017.05.017

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。